The 41 references in paper F. Dzgoeva U., M. Sopoev Y., T. Bestaeva L., O. Khamitsaeva V., D. Gigolaev A., Ф. Дзгоева У., М. Сопоев Ю., Т. Бестаева Л., О. Хамицаева В., Д. Гиголаев А. (2015) “Фактор роста фибробластов-23 и сердечнососудистые осложнения при хронической болезни почек // The fibroblast growth factor-23 and cardiovascular complications in chronic kidney disease” / spz:neicon:nefr:y:2015:i:5:p:49-56

1
Мухин НА. Хроническая болезнь почек. Клин фармакол и тер 2011;4:70-75 [Muhin NA. Chronic kidney disease. Klin farmakol i ter 2011;4:70-75]
(check this in PDF content)
2
Смирнов АВ, Румянцев АШ, Добронравов ВА, Каюков ИГ. XXI век – время интегративной нефрологии. Нефрология 2015;2:26-32 [Smirnov AV, Rumyantsev Ash, Dobronravov VA, Kayukov IG. The twenty-first century integrative Nephrology. Nefrologiya 2015;2:26-32]
(check this in PDF content)
3
Dhingra R, Gaziano JM, Djoussé L. Chronic kidney disease and the risk of heart failure in men.Circ Heart Fail 2011;4: 138–144
(check this in PDF content)
4
Middleton RJ, Parfrey PS, Foley RN. Left ventricular hypertrophy in the renal patient. J Am Soc Nephrol 2001; 12: 1079–1084
(check this in PDF content)
5
Wolf M. Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int 2012; 82: 737–747
(check this in PDF content)
6
Ix JH, Katz R, Kestenbaum BR. et al. Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study). J Am Coll Cardiol 2012; 60:200–207
(check this in PDF content)
7
Gutiérrez OM, Mannstadt M, Isakova T et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359: 584–592
(check this in PDF content)
8
Faul C, Amaral AP, Oskouei B et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011;121: 4393–4408
(check this in PDF content)
9
Scialla J, Lau W, Reilly M et al. Chronic Renal Insufficiency Cohort Study Investigators. Fibroblast growth factor 23 is not associated with and does not induce arterial calcification. Kidney Int 2013; 83: 1159–1168
(check this in PDF content)
10
Добронравов ВА. Современный взгляд на патофизиологию вторичного гиперпаратиреоза: Роль фактора роста фибробластов-23 и Klotho. Нефрология 2011;4:11-20 [Dobronravov VA. Modern view on the pathophysiology of secondary hyperparathyroidism: the Role of fibroblast growth factor-23 and Klotho. Nefrologiya 2011;4:11-20]
(check this in PDF content)
11
Ketteler M, Biggar R. FGF23: more a matter of the heart than of the vessels? Nephrol Dial Transplant 2014; 29: 1987-1988
(check this in PDF content)
12
Милованова ЛЮ, Милованов ЮС, Козловская ЛВ, Мухин НА. Новые маркеры кардиоренальных взаимосвязей при хронической болезни почек. Тер арх 2013; 6:17-24 [Milovanova LYu, Milovanov YuS, Kozlovskaya LV, Muhin NA. New markers of cardiorenal interactions in chronic kidney disease. Ter arh 2013; 6:17-24]
(check this in PDF content)
13
Lutsey PL, Alonso A, Selvin E et al. Fibroblast growth factor-23 and incident coronary heart disease, heart failure, and cardiovascular mortality: the atherosclerosis risk in communities study. J Am Heart Assoc 2014;3:e000936
(check this in PDF content)
14
Isakova T, Craven TE, Lee J et al. Fibroblast Growth Factor 23 and Incident CKD in Type 2 Diabetes. JASN 2015 ; 10 : 29-38
(check this in PDF content)
15
Wang L, Song Y, Manson JE et al. Circulating 25-hydroxyvitamin D and risk of cardiovascular disease: a meta-analysis of prospective studies. Circ Cardiovasc Qual Outcomes 2012;5:819829.
(check this in PDF content)
16
Рафрафи Х., Румянцев А.Ш. Статус витамина D и состояние сердечно-сосудистой системы у пациентов с хронической болезнью почек С5д стадии. Нефрология 2015; 19(4)51-54 [Rafrafi H., Rumjancev A.Sh. Status vitamina D i sostojanie serdechno-sosudistoj sistemy u pacientov s hronicheskoj bolezn’ju pochek S5d stadii. Nefrologija 2015; 19(4)51-54].
(check this in PDF content)
17
Cozzolino M, Cosa F, Ciceri F et al. Vascular calcification in chronic kidney disease. EMJ Neph. 2013;1:46-51.
(check this in PDF content)
18
Desai CS, Ning H, Lloyd-Jones DM et al. Competing cardiovascular outcomes associated with electrocardiographic left ventricular hypertrophy: the Atherosclerosis Risk in Communities Study. Heart 2012; 98:330-334
(check this in PDF content)
19
Isakova T, Xie H, Yang W et al. Chronic Renal Insufficiency Cohort (CRIC) Study Group Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011; 305: 2432–2439
(check this in PDF content)
20
Батюшин ММ, Левицкая ЕС, Терентьев ВП и др. Оценка влияния «почечных» факторов риска и параметров коронарной бляшки на сердечно-сосудистый прогноз у больных с ишемической болезнью сердца. Кардиоваскулярная терапия и профилактика 2011;4:59-62 3 [Batyushin MM, Levitskaya ES, Terentev VP et al. Evaluation of the effect of renal risk factors and parameters of coronary plaques on cardiovascular prognosis in patients with coronary heart disease. Kardiovaskulyarnaya terapiya i profilaktika2011;4:59-62 3]
(check this in PDF content)
21
Sloan A, Isakova T, Gutiérrez OM et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011; 121: 4393–4408
(check this in PDF content)
22
Gutiérrez OM, Wolf M, Taylor EN et al. Fibroblast growth factor 23, cardiovascular disease risk factors, and phosphorus intake in the health professionals follow-up study. Clin J Am Soc Nephrol 2011; 6: 2871–2878
(check this in PDF content)
23
Scialla JJ, Xie H, Rahman M et al. Fibroblast Growth Factor-23 and Cardiovascular Events in CKD JASN February 2014 ;25: 349-360
(check this in PDF content)
24
Ärnlöv J, Carlsson AC, Sundström J et al. Higher fibroblast growth factor-23 increases the risk of all-cause and cardiovascular mortality in the community. Kidney Int 2013: 83:160–166
(check this in PDF content)
25
Seiler S, Cremers B, Rebling NM et al. The phosphatonin fibroblast growth factor 23 links calcium-phosphate metabolism with left-ventricular dysfunction and atrial fibrillation. Eur Heart J 2011; 32: 2688–2696
(check this in PDF content)
26
Bengtson LGS, Lutsey PL, Loehr LR et al. Fibroblast Growth Factor-23 and Incident Coronary Heart Disease, Heart Failure, and Cardiovascular Mortality: The Atherosclerosis Risk In Communities Study. J Am Heart Assoc 2014; 3: e000936
(check this in PDF content)
27
Mathew JS, Sachs MC, Katz R et al. Fibroblast growth factor-23 and incident atrial fibrillation: The Multi-Ethnic Study of Atherosclerosis (MESA) and the Cardiovascular Health Study (CHS). Circulation 2014;130:298-307
(check this in PDF content)
28
Hsu JJ, Katz R, Ix J et al. Association of fibroblast growth factor-23 with arterial stiffness in the Multiethnic Study of Atherosclerosis (MESA). Nephrol Dial Transplant 2014;29:2099-2105
(check this in PDF content)
29
Дзгоева ФУ, Гатагонова ТМ, Бестаева ТЛ и др. Остеопротегерин и фактор роста фибробластов (FGF-23) в развитии кардиоваскулярных осложнений при хронической болезни почек. Тер арх 2014;6:63-69 [Dzgoeva FU, Gatagonova TM, Bestaeva TL et al. The osteoprotegerin and fibroblast growth factor (FGF-23) in the development of cardiovascular complications in chronic kidney disease. Ter arh 2014;6:63-69]
(check this in PDF content)
30
Дзгоева ФУ, Гатагонова ТМ, Кочисова ЗХ и др. Взаимосвязь типов ремоделирования левого желудочка с показателями оксидативного стресса, фосфорно-кальциевого и липидного обмена при терминальной почечной недостаточности. Нефрология 2013 ;5: 35 38 [Dzgoeva FU, Gatagonova TM, Kochisova ZH et al. The correlation between types of left ventricular remodeling with indicators of oxidative stress, calcium and phosphorus and lipid metabolism in end-stage renal failure. Nefrologiya 2013 ;5: 35-38]
(check this in PDF content)
31
Munoz MJ, Isakova T, Ricardo AC et al. Cohort ftCRI. Fibroblast growth factor 23 and inflammation in CKD. Clin J Am Soc Nephrol 2012; 7:1155-1162
(check this in PDF content)
32
Parker BD, Schurgers LJ, Brandenburg VM et al. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med 2010; 152: 640-648.
(check this in PDF content)
33
Arnlov J, Carlsson AC, Sundstrom J et al. Higher fibroblast growth factor-23 increases the risk of all-cause and cardiovascular mortality in the community. Kidney Int 2013; 83:160-166.
(check this in PDF content)
34
Rosamond WD, Chang PP, Baggett C et al. Classification of heart failure in the Atherosclerosis Risk in Communities (ARIC) Study: a comparison of diagnostic criteria. Circ Heart Fail 2012; 5:152-159.
(check this in PDF content)
35
Добронравов ВА, Богданова EО. Патогенез нарушений обмена фосфатов при хронической болезни почек: все ли так ясно, как кажется? Нефрология 2014;2: 42-47 [Dobronravov VA, Bogdanova EO. The pathogenesis of disorders of metabolism of phosphate in chronic kidney disease: everything is so clear as it seems? Nefrologiya 2014;2: 42-47]
(check this in PDF content)
36
Nakano C, Hamano T, Fujii N et al. Intact fibroblast growth factor 23 levels predict incident cardiovascular event before but not after the start of dialysis. Bone 2012 ; 50:1266–1274
(check this in PDF content)
37
Hu MC, Shi M, Zhang J et al. Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol 2011;22: 124–136
(check this in PDF content)
38
Foley RN, Collins AJ, Herzog CA et al. Serum phosphate and left ventricular hypertrophy in young adults: the coronary artery risk development in young adults study. Kidney Blood Press Res 2009; 32:37-44
(check this in PDF content)
39
Lopez FL, Agarwal SK, Grams ME et al. Relation of serum phosphorus levels to the incidence of atrial fibrillation (from the Atherosclerosis Risk in Communities [ARIC] Study).Am J Cardiol 2013; 111:857-862
(check this in PDF content)
40
Di Marco GS, Reuter S, Kentrup D et al. Treatment of established left ventricular hypertrophy with fibroblast growth factor receptor blockade in an animal model of CKD. Nephrol. Dial. Transplant 2014;29 : 2028-2035
(check this in PDF content)
41
Nagano N, Miyata S, Abe M et al. Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF-23 in renal failure rats. Kidney Int 2006; 69:531-537 Авторы заявляют об отсутствии конфликта интересов.
(check this in PDF content)